Proteros announces a USD 12.9 million Series A Financing of Rodin Therapeutics
Proteros biostructures GmbH announced the completion of a Series A financing round of Rodin Therapeutics, Inc, located in Boston, MA. Rodin Therapeutics, founded by Atlas Venture and Proteros, is a capital efficient approach with the mission to apply insights in epigenetics to novel therapeutics for neurological disorders. Current investors Atlas Venture and Johnson and Johnson Innovation Center led the financing round. Rodin will use the proceeds in the amount of USD 12.9 million to advance its pipeline of selective epigenetic modulators towards the clinic.
Since its inception in March 2013, Rodin has advanced its internal pipeline of epigenetic modulators and an additional chemical series, obtained under an exclusive license from the Broad Institute. The Rodin approach is a combination of high potential biology, unique chemistry, a strong team and Proteros' key capabilities in structure accelerated lead discovery, which enable an orthogonal evaluation of the interactions of small molecules and epigenetic targets.
The Rodin team comprises senior executives of Atlas, Johnson and Johnson Innovation Center and Proteros. The company has also assembled an esteemed Scientific Advisory Board of leaders in the field of neurology and epigenetics.
Torsten Neuefeind, Chief Executive Officer of Proteros commented: 'Rodin is the first proprietary lead discovery project initiated by Proteros that we successfully transferred into a joint venture with industry-renowned partners and that now closed its second financing round. This is an important step for Rodin and a capital efficient business model for all stakeholders.'
Other news from the department business & finance
